Yu Jin Lim, Sea-Won Lee, Noorie Choi, Jeanny Kwon, Keun-Yong Eom, Eunyoung Kang, Eun-Kyu Kim, Jee Hyun Kim, Yu Jung Kim, Se Hyun Kim, So Yeon Park, In Ah Kim
Cancer Res Treat. 2018;50(4):1140-1148. Published online December 7, 2017
Purpose
This study aimed to identify predictors for distant metastatic behavior and build a related prognostic nomogram in breast cancer.
Materials and Methods
A total of 1,181 patients with non-metastatic breast cancer between 2003 and 2011 were analyzed. To predict the probability of distant metastasis, a nomogram was constructed based on prognostic factors identified using a Cox proportional hazards model.
Results
The 7-year overall survival and 5-year post-progression survival of locoregional versus distant recurrence groups were 67.6% versus 39.1% (p=0.027) and 54.2% versus 33.5% (p=0.043), respectively. Patients who developed distant metastasis showed early and late mortality risk peaks within 3 and after 5 years of follow-up, respectively, but a broad and low risk increment was observed in other patients with locoregional relapse. In multivariate analysis of distant metastasis-free interval, age (≥ 45 years vs. < 45 years), molecular subtypes (luminal A vs. luminal B, human epidermal growth receptor 2, and triple negative), T category (T1 vs. T2-3 and T4), and N category (N0 vs. N1 and N2-3) were independently associated (p < 0.05 for all). Regarding the significant factors, a well-validated nomogram was established (concordance index, 0.812). The risk score level of patients with initial brain failure was higher than those of non-brain sites (p=0.029).
Conclusion
The nomogram could be useful for predicting the individual probability of distant recurrence in breast cancer. In high-risk patients based on the risk scores, more aggressive systemic therapy and closer surveillance for metastatic failure should be considered.
Citations
Citations to this article as recorded by
Predicting Patterns of Distant Metastasis in Breast Cancer Patients following Local Regional Therapy Using Machine Learning Audrey Shiner, Alex Kiss, Khadijeh Saednia, Katarzyna J. Jerzak, Sonal Gandhi, Fang-I Lu, Urban Emmenegger, Lauren Fleshner, Andrew Lagree, Marie Angeli Alera, Mateusz Bielecki, Ethan Law, Brianna Law, Dylan Kam, Jonathan Klein, Christopher J. Pinard, Ale Genes.2023; 14(9): 1768. CrossRef
Nomograms for Predicting Specific Distant Metastatic Sites and Overall Survival of Breast Invasive Ductal Carcinoma Patients After Surgery: A Large Population-Based Study Yuqian Feng, Yiting Zhang, Yuying Xiang, Kaibo Guo, Huimin Jin, Shanming Ruan, Zhuoya Guan Frontiers in Surgery.2022;[Epub] CrossRef
Cost-effectiveness of postmastectomy hypofractionated radiation therapy vs conventional fractionated radiation therapy for high-risk breast cancer Jing Yang, Shu-Nan Qi, Hui Fang, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Wei-Hu Wang, Yong Yang, Yu Tang, Hua Ren, Bo Chen, Ning-Ning Lu, Yuan Tang, Ning Li, Hao Jing, Shu-Lian Wang, Ye-Xiong Li The Breast.2021; 58: 72. CrossRef
Prediction of distant metastatic recurrence by tumor-infiltrating lymphocytes in hormone receptor-positive breast cancer Koji Takada, Shinichiro Kashiwagi, Yuka Asano, Wataru Goto, Rika Kouhashi, Akimichi Yabumoto, Sae Ishihara, Tamami Morisaki, Masatsune Shibutani, Hiroaki Tanaka, Kosei Hirakawa, Masaichi Ohira BMC Women's Health.2021;[Epub] CrossRef
Nomogram for the personalisation of radiotherapy treatments in breast cancer patients Inmaculada Beato Tortajada, Carlos Ferrer Albiach, Virginia Morillo Macias The Breast.2021; 60: 255. CrossRef
Prognostic Factors and Nomograms to Predict Overall and Cancer-Specific Survival for Children with Wilms’ Tumor Fucai Tang, Hanbin Zhang, Zechao Lu, Jiamin Wang, Chengwu He, Zhaohui He Disease Markers.2019; 2019: 1. CrossRef
Score for the Survival Probability in Metastasis Breast Cancer: A Nomogram-Based Risk Assessment Model Zhenchong Xiong, Guangzheng Deng, Xinjian Huang, Xing Li, Xinhua Xie, Jin Wang, Zeyu Shuang, Xi Wang Cancer Research and Treatment.2018; 50(4): 1260. CrossRef
Purpose This study evaluates the long-term results of definitive radiotherapy (RT) for early glottic cancer. Clinical and treatment factors related to local control and patterns of failure are analyzed. Materials and Methods We retrospectively reviewed 222 patients with T1-2N0 squamous cell carcinoma of the glottic larynx treated with definitive RT from 1981 to 2010. None of the patients received elective nodal RT or combined chemotherapy. The median total RT dose was 66 Gy. The daily fraction size was < 2.5 Gy in 69% and 2.5 Gy in 31% of patients. The RT field extended from the hyoid bone to the cricoid cartilage.
Results The median age was 60 years, and 155 patients (70%) had T1 disease. The 5-year rates of local recurrence-free survival (LRFS) and ultimate LRFS with voice preservation were 87.8% and 90.3%, respectively. T2 (hazard ratio [HR], 2.30; 95% confidence interval [CI], 1.08 to 4.94) and anterior commissural involvement (HR, 3.37; 95% CI, 1.62 to 7.02) were significant prognostic factors for LRFS. In 34 patients with local recurrence, tumors recurred in the ipsilateral vocal cord in 28 patients. There were no contralateral vocal cord recurrences. Most acute complications included grade 1-2 dysphagia and/or hoarseness. There was no grade 3 or greater chronic toxicity.
Conclusion Definitive RT achieved a high cure rate, voice preservation, and tolerable toxicity in early glottic cancer. T2 stage and anterior commissural involvement were prognostic factors for local control. Further optimization of the RT method is needed to reduce the risk of ipsilateral tumor recurrence.
Citations
Citations to this article as recorded by
Superior Regional Control and Laryngeal Function Preservation With Radiotherapy Versus Partial Laryngectomy: A Propensity Score‐Matched Analysis of 562 Early Glottic Cancer Patients Shaoqiu Zhang, Ruichen Li, Yang Zhao, Liting Zhu, Ming Guo, Xiaoshen Wang, Yi Zhu Head & Neck.2025;[Epub] CrossRef
Dosimetric comparison between carotid-sparing IMRT and 3DCRT in early glottic cancer patients treated with definitive radiation therapy Harkirat Kaur, Niketa Thakur, Ramita Sharma, Meena Sudan, Neeraj Jain, Supreet Kaur, Priyanka Lehal Journal of Cancer Research and Therapeutics.2024; 20(1): 327. CrossRef
Assessment and validation of glottic motion using cone-beam CT and real-time cine MRI Seok-Joo Chun, Jaeman Son, Seonghee Kang, Chang Heon Choi, Jung-in Kim, Young-Il Kim, Joo Ho Lee, Jin Ho Kim, Hong-Gyun Wu Strahlentherapie und Onkologie.2024; 200(5): 418. CrossRef
Oncological and Functional Outcomes for Horizontal Glottectomy: A Systematic Review Matteo Fermi, Alfredo Lo Manto, Cecilia Lotto, Giulia Cianci, Francesco Mattioli, Daniele Marchioni, Livio Presutti, Ignacio Javier Fernandez Journal of Clinical Medicine.2023; 12(6): 2261. CrossRef
Prospective Observational Comparative Study of Response and Toxicities in Early Glottic Cancer Using Telecobalt Versus 3D-CRT Sanchayan Mandal, Tamohan Chaudhuri, Dhrubajyoti Mukhopadhyay Indian Journal of Otolaryngology and Head & Neck Surgery.2022; 74(S2): 1725. CrossRef
Neck Dissection in Salvage Surgery for Larynx Cancer: National Cancer Database Review Tirth R. Patel, Jaijeet Toor, Bobby A. Tajudeen, Mihir Bhayani, Samer Al-Khudari Annals of Otology, Rhinology & Laryngology.2022; 131(4): 379. CrossRef
Hypofractionated radiotherapy for early stage glottic cancer: efficacy of 3.5 Gy per fraction Tae Hoon Lee, Joo Ho Lee, Seong Keun Kwon, Eun-Jae Chung, Hong-Gyun Wu Radiation Oncology Journal.2022; 40(2): 120. CrossRef
Early‐stage vocal cord cancer treated with hypofractionated radiotherapy to the larynx with or without concurrent chemotherapy Alexandra N. de Leo, Roi Dagan, Christopher G. Morris, Adam L. Holtzman, Kathryn E. Hitchcock, Curtis M. Bryant, Robert J. Amdur, William M. Mendenhall Head & Neck.2022; 44(11): 2513. CrossRef
Long-term impact of smoking cessation on new glottic cancer events in patients with early glottic cancer Min-Su Kim, Hong-Gyun Wu, Myung-Whun Sung, Tack-Kyun Kwon Acta Otorhinolaryngologica Italica.2022; 42(6): 525. CrossRef
Laser Microsurgery Versus Radiotherapy Versus Open Partial Laryngectomy for T2 Laryngeal Carcinoma: A Systematic Review of Oncological Outcomes Flaminia Campo, Jacopo Zocchi, Massimo Ralli, Daniele De Seta, Francesca Yoshie Russo, Diletta Angeletti, Antonio Minni, Antonio Greco, Raul Pellini, Marco de Vincentiis Ear, Nose & Throat Journal.2021; 100(1_suppl): 51S. CrossRef
Occult Lymph Node Metastasis in Early‐Stage Glottic Cancer in the National Cancer Database Tirth R. Patel, Michael Eggerstedt, Jaijeet Toor, Bobby A. Tajudeen, Inna Husain, Kerstin Stenson, Samer Al‐Khudari The Laryngoscope.2021;[Epub] CrossRef
Individualized quality of life benefit and cost-effectiveness estimates of proton therapy for patients with oropharyngeal cancer N. Patrik Brodin, Rafi Kabarriti, Clyde B. Schechter, Mark Pankuch, Vinai Gondi, Shalom Kalnicki, Madhur K. Garg, Wolfgang A. Tomé Radiation Oncology.2021;[Epub] CrossRef
Early glottic cancer recurrence: A critical review on its current management Luca Giovanni Locatello, Chiara Bruno, Oreste Gallo Critical Reviews in Oncology/Hematology.2021; 160: 103298. CrossRef
TLM Outcomes in Elderly Patients with Glottic Pre-Malignancy and Early Malignancy; A 12-Year Retrospective Study Heidi Jones, Elizabeth Ross, Jemy Jose Annals of Otology, Rhinology & Laryngology.2021; 130(12): 1392. CrossRef
Prognostic value of the maximum standardized uptake value for the locoregional control in early glottic cancer Donghyun Kim, Yongkan Ki, Jihyeon Joo, Hosang Jeon, Dahl Park, Jiho Nam, Wontaek Kim Radiation Oncology Journal.2021; 39(4): 297. CrossRef
Outcomes of carotid‐sparing IMRT for T1 glottic cancer: Comparison with conventional radiation Abdallah S.R. Mohamed, Blaine D. Smith, Joshua B. Smith, Parag Sevak, Jessica S. Malek, Aasheesh Kanwar, Theodora Browne, G. Brandon Gunn, Adam S. Garden, Steven J. Frank, William H. Morrison, Jack Phan, Mark Zafereo, Heath Skinner, Stephen Y. Lai, Kather The Laryngoscope.2020; 130(1): 146. CrossRef
Helical Radiotherapy in Early Laryngeal Cancers Could Lead to Excess Local Recurrence: Lessons From a Phase II Prospective Study S. Chatterjee, I. Mallick, S. Chakraborty, S. Prasath, M. Arunsingh, R.B. Achari, B. Arun, C. Nallathambi, A. Pattatheyil, S. Sen Clinical Oncology.2020; 32(2): e67. CrossRef
MACC1 expression is an indicator of recurrence in early-stage glottic cancer Takuma Makino, Yorihisa Orita, Yuka Gion, Tomoyasu Tachibana, Soshi Takao, Hidenori Marunaka, Kentaro Miki, Naoki Akisada, Yusuke Akagi, Tadashi Yoshino, Kazunori Nishizaki, Yasuharu Sato Japanese Journal of Clinical Oncology.2020; 50(4): 392. CrossRef
Is tailored management better than salvage in laryngeal squamous cell carcinomas Bhargaw Ilapakruty, Vishal U. S. Rao Head & Neck.2020; 42(2): 357. CrossRef
Chemoradiotherapy for high-risk stage II laryngeal cancer Satoshi Hamauchi, Tomoya Yokota, Yusuke Onozawa, Hirofumi Ogawa, Tsuyoshi Onoe, Tomoyuki Kamijo, Yoshiyuki Iida, Tetsuro Onitsuka, Hirofumi Yasui International Journal of Clinical Oncology.2020; 25(9): 1596. CrossRef
Transoral laser microsurgery for glottic cancer in the elderly: Efficacy and safety Juan P. Rodrigo, Fabian García‐Velasco, Petra Ambrosch, Vincent Vander Poorten, Carlos Suárez, Andrés Coca‐Pelaz, Primoz Strojan, Kate Hutcheson, Benedikt J. Folz, Manuel Bernal‐Sprekelsen, Alessandra Rinaldo, Carl E. Silver, Alfio Ferlito Head & Neck.2019; 41(6): 1816. CrossRef
Early Closure of a Phase 1 Clinical Trial for SABR in Early-Stage Glottic Cancer Byung-Hee Kang, Tosol Yu, Jin Ho Kim, Jong Min Park, Jung-In Kim, Eun-Jae Chung, Seong Keun Kwon, Ji-Hoon Kim, Hong-Gyun Wu International Journal of Radiation Oncology*Biology*Physics.2019; 105(1): 104. CrossRef
Prognostic factors in patients with T1 glottic cancer treated with radiotherapy A. Mucha-Małecka, A. Chrostowska, K. Urbanek, K. Małecki Strahlentherapie und Onkologie.2019; 195(9): 792. CrossRef
Hypofractionated radiotherapy for early glottic cancer: a retrospective interim analysis of a single institution Jeong Won Lee, Jeong Eun Lee, Junhee Park, Jin Ho Sohn, Dongbin Ahn Radiation Oncology Journal.2019; 37(2): 82. CrossRef
Outcome of Early-Stage Glottic Laryngeal Carcinoma Patients Treated with Radical Radiotherapy Using Different Techniques Oguz Cetinayak, Ersoy Dogan, Ahmet Kuru, Nesrin Akturk, Barbaros Aydin, Cenk Umay, Ilhami Er, Fadime Akman Journal of Oncology.2019; 2019: 1. CrossRef
Involvement of the Anterior Commissure in Early Glottic Cancer (Tis-T2): A Review of the Literature Martine Hendriksma, Elisabeth V. Sjögren Cancers.2019; 11(9): 1234. CrossRef
Patterns of failure for early-stage glottic carcinoma Fatma Sert, Isa Kaya, Kerem Ozturk, Mustafa Esassolak Journal of Cancer Research and Therapeutics.2019; 15(3): 576. CrossRef
Oncologic outcomes of KTP laser surgery versus radiation for T1 glottic carcinoma Jamal Ahmed, Ahmed Sherif Gabr Ibrahim, Laura M. Freedman, David E. Rosow The Laryngoscope.2018; 128(5): 1052. CrossRef
Study design and early result of a phase I study of SABR for early‐stage glottic cancer Tosol Yu, Chan Woo Wee, Noorie Choi, Hong‐Gyun Wu, Hyun‐Cheol Kang, Jong Min Park, Jung‐In Kim, Jin Ho Kim, Tack‐Kyun Kwon, Eun‐Jae Chung The Laryngoscope.2018; 128(11): 2560. CrossRef
Clinicopathological Characteristics and Survival Rate of Patients with Laryngeal Squamous Cell Carcinoma: A Retrospective Study during 2011–2017 in Yazd, Iran Shokouh T Zahir, Koorosh Rahmani, Meisam Mehri, Mohammad Shafiee, Seyed M Reza Mortazavizadeh International Journal of Phonosurgery & Laryngology.2018; 8(2): 65. CrossRef
Endoscopic-assisted selective neck dissection via small lateral neck incision for early-stage (T1-2N0M0) head and neck squamous cell carcinoma: 3-year follow-up results Faya Liang, Song Fan, Ping Han, Qian Cai, Peiliang Lin, Renhui Chen, Shitong Yu, Xiaoming Huang Surgical Endoscopy.2017; 31(2): 894. CrossRef
Transoral laser microsurgery versus radiotherapy for T2 glottic squamous cell carcinoma: a systematic review of local control outcomes L. Warner, K. Lee, J.J. Homer Clinical Otolaryngology.2017; 42(3): 629. CrossRef
Impact of Close and Positive Margins in Transoral Laser Microsurgery for Tis–T2 Glottic Cancer Ivana Fiz, Francesco Mazzola, Francesco Fiz, Filippo Marchi, Marta Filauro, Alberto Paderno, Giampiero Parrinello, Cesare Piazza, Giorgio Peretti Frontiers in Oncology.2017;[Epub] CrossRef
Volumetric modulated arc radiotherapy of the whole larynx, followed by a single affected vocal cord, for T1a glottic cancer: Dosimetric analysis of a case SEUNG-GU YEO Molecular and Clinical Oncology.2016; 4(3): 429. CrossRef
Purpose
The purpose of this study was to evaluate whether an exogenous epidermal growth factor (EGF) could induce anti-tumor and radiosensitizing effects in vivo.
Materials and Methods
BALB/c-nu mice that were inoculated with A431 (human squamous cell carcinoma) cells in the right hind legs were divided into five groups: I (no treatment), II (EGF for 6 days), III (EGF for 20 days), IV (radiotherapy [RT]), and V (RT plus concomitant EGF). EGF was administered intraperitoneally (5 mg/kg) once a day and the RT dose was 30 Gy in six fractions. Hematoxylin and eosin (H&E) stained sections of tumor, liver, lung, and kidney tissues were investigated. Additionally, tumors were subjected to immunohistochemistry staining with caspase-3.
Results
EGF for 6 days decreased tumor volume, but it approached the level of the control group at the end of follow-up (p=0.550). The duration of tumor shrinkage was prolonged in group V while the slope of tumor re-growth phase was steeper in group IV (p=0.034). EGF for 20 days decreased tumor volume until the end of the observation period (p < 0.001). Immunohistochemistry revealed that mice in group V showed stronger intensity than those in group IV. There were no abnormal histological findings upon H&E staining of the normal organs.
Conclusion
EGF-induced anti-tumor effect was ascertained in the xenograft mouse models with A431 cells. Concomitant use of EGF has the potential role as a radiosensitizer in the design of fractionated irradiation.
Citations
Citations to this article as recorded by
Receptor Elimination by E3 Ubiquitin Ligase Recruitment (REULR): A Targeted Protein Degradation Toolbox Dirk H. Siepe, Lora K. Picton, K. Christopher Garcia ACS Synthetic Biology.2023; 12(4): 1081. CrossRef
Identification of Genes Involved in EGF-induced Apoptosis Using CRISPR/Cas9 Knockout Screening: Implications for Novel Therapeutic Targets in EGFR-Overexpressing Cancers Jae Sik Kim, Joo Ho Lee, Sang-Rok Jeon, Yongsub Kim, Seung Hyuck Jeon, Hong-Gyun Wu Cancer Research and Treatment.2023; 55(3): 737. CrossRef
DNA damage alters EGFR signaling and reprograms cellular response via Mre-11 Yael Volman, Ruth Hefetz, Eithan Galun, Jacob Rachmilewitz Scientific Reports.2022;[Epub] CrossRef
Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts Jiadong Cui, Yan Zhang, Di Su, Tao Li, Yu Li Thoracic Cancer.2018; 9(9): 1156. CrossRef
Biased signaling downstream of epidermal growth factor receptor regulates proliferative versus apoptotic response to ligand Remah Ali, Wells Brown, Stephen Connor Purdy, V. Jo Davisson, Michael K. Wendt Cell Death & Disease.2018;[Epub] CrossRef
The paradoxical functions of EGFR during breast cancer progression Remah Ali, Michael K Wendt Signal Transduction and Targeted Therapy.2017;[Epub] CrossRef
Efficacy of radiotherapy for the treatment of cystic echinococcosis in naturally infected sheep Rui Mao, Wen-Bao Zhang, Hong-Zhi Qi, Tao Jiang, Ge Wu, Peng-Fei Lu, Abudula Ainiwaer, Ge Shang, Lin Xu, Jie Hao, Xi Shou, Hai-Tao Li, Jun Li, Song-An Zhang, Yong-Xing Bao, Hao Wen Infectious Diseases of Poverty.2017;[Epub] CrossRef
Epidermal Growth Factor Enhances Cellular Uptake of Polystyrene Nanoparticles by Clathrin-Mediated Endocytosis Le Phuc, Akiyoshi Taniguchi International Journal of Molecular Sciences.2017; 18(6): 1301. CrossRef